Document is current
Any future updates will be listed below
-
Authors
Monberg, Matthew J. https://orcid.org/0009-0006-7462-4782
Keefe, Steve
Karantza, Vassiliki
Tryfonidis, Konstantinos
Toker, Sarper
Mejia, Jaime
Orlowski, Robert
Haiderali, Amin
Prabhu, Vimalanand S.
Aktan, Gursel
-
Funding
Funding for this research was provided by:
Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
- License Information
-
More Information
Article History
Received: 25 April 2024
Accepted: 4 September 2024
First Online: 25 October 2024
Declarations
:
: Matthew J. Monberg, Steve Keefe, Vassiliki Karantza, Konstantinos Tryfonidis, Sarper Toker, Jaime Mejia, Robert Orlowski, Amin Haiderali, Vimalanand S. Prabhu and Gursel Aktan are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Pembrolizumab is manufactured by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
